SXTP (60 Degrees Pharmaceuticals) Moat Score: 2/10 (As of Jul. 02, 2026)


SXTP 60 Degrees Pharmaceuticals Inc SXTP
44 GF Score
Price $1.78
GF Value $2.05
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is 60 Degrees Pharmaceuticals Moat Score?

60 Degrees Pharmaceuticals SXTP +1.71% 44 Moat Score is 2 as of Jul. 02, 2026. GuruFocus rates SXTP with a GF Score™ of 44/100 and a GF Value™ of $2.05 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,400 Biotechnology companies, 60 Degrees Pharmaceuticals ranks better than 58.07% on this metric.

60 Degrees Pharmaceuticals has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

60 Degrees Pharmaceuticals has No Moat: 60 Degrees Pharmaceuticals Inc has minimal market leadership and lacks significant intellectual property or regulatory barriers. The pharmaceutical industry is highly competitive, and the company does not possess strong brand strength or customer loyalty, resulting in a weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes 60 Degrees Pharmaceuticals might have No Moat - Very weak/transient advantages.

60 Degrees Pharmaceuticals  (NAS:SXTP) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

60 Degrees Pharmaceuticals Moat Score Related Terms

SXTP vs GLMD, FBLG, CELZ: Moat Score Comparison

For the Biotechnology subindustry, 60 Degrees Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

60 Degrees Pharmaceuticals Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 60 Degrees Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where 60 Degrees Pharmaceuticals's Moat Score falls into.


SXTP
44GF Score
60 Degrees Pharmaceuticals Inc SXTP
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
60 Degrees Pharmaceuticals (SXTP) has a Moat Score of 2 as of Jul. 02, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, 60 Degrees Pharmaceuticals ranks #587 out of 1400 companies in the Biotechnology industry, placing it in the top 41.9%.
Is 60 Degrees Pharmaceuticals' Moat Score too high?
60 Degrees Pharmaceuticals' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. 60 Degrees Pharmaceuticals' value of 2 is 0% at this industry median. Based on the distribution chart, 60 Degrees Pharmaceuticals ranks #587 out of 1400 companies in the Biotechnology industry, which is above the industry midpoint. Overall, 60 Degrees Pharmaceuticals has a GF Score™ of 44/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does 60 Degrees Pharmaceuticals' Moat Score compare to GLMD and FBLG?
According to the Biotechnology industry distribution chart, 60 Degrees Pharmaceuticals ranks #587 out of 1400 companies for Moat Score. This puts 60 Degrees Pharmaceuticals in the upper half of its industry. The industry median Moat Score is 2.00. 60 Degrees Pharmaceuticals' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 60 Degrees Pharmaceuticals's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 60 Degrees Pharmaceuticals's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 60 Degrees Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, 60 Degrees Pharmaceuticals (SXTP) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.05, compared to a current price of $1.78 — trading 13.2% below its estimated fair value. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. 60 Degrees Pharmaceuticals' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For 60 Degrees Pharmaceuticals (SXTP), the current Moat Score is 2 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 60 Degrees Pharmaceuticals (SXTP) Overvalued in 2026?

Based on GuruFocus' analysis, 60 Degrees Pharmaceuticals stock appears to be undervalued. The current stock price of $1.78 is trading 13.2% below its estimated GF Value™ of $2.05. GuruFocus considers 60 Degrees Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for SXTP:

  • Moat Score: 2
  • GF Value™: $2.05 vs. price of $1.78 (13.2% below fair value)
  • GF Score™: 44/100 with 5 warning signs
  • Industry Position: 0% at the Biotechnology median (#587 of 1400)

No single metric tells the full story. See the SXTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

60 Degrees Pharmaceuticals Business Description

Address 1025 Connecticut Avenue NW, Suite 1000, Washington, D.C, WA, USA, 20036
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
44GF Score

Get the complete analysis for SXTP

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.78
Price
$2.05
GF Value